These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 12843383)

  • 1. Biomedicine. Ataxin-1 regulators in the spotlight.
    Heintz N
    Science; 2003 Jul; 301(5629):59-60. PubMed ID: 12843383
    [No Abstract]   [Full Text] [Related]  

  • 2. Polyglutamine neurodegeneration: minding your Ps and Qs.
    Paulson H
    Nat Med; 2003 Jul; 9(7):825-6. PubMed ID: 12835695
    [No Abstract]   [Full Text] [Related]  

  • 3. Interaction of Akt-phosphorylated ataxin-1 with 14-3-3 mediates neurodegeneration in spinocerebellar ataxia type 1.
    Chen HK; Fernandez-Funez P; Acevedo SF; Lam YC; Kaytor MD; Fernandez MH; Aitken A; Skoulakis EM; Orr HT; Botas J; Zoghbi HY
    Cell; 2003 May; 113(4):457-68. PubMed ID: 12757707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serine 776 of ataxin-1 is critical for polyglutamine-induced disease in SCA1 transgenic mice.
    Emamian ES; Kaytor MD; Duvick LA; Zu T; Tousey SK; Zoghbi HY; Clark HB; Orr HT
    Neuron; 2003 May; 38(3):375-87. PubMed ID: 12741986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SUMO-1 interacts with mutant ataxin-1 and colocalizes to its aggregates in Purkinje cells of SCA1 transgenic mice.
    Kang S; Hong S
    Arch Ital Biol; 2010 Dec; 148(4):351-63. PubMed ID: 21308649
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amino acids in a region of ataxin-1 outside of the polyglutamine tract influence the course of disease in SCA1 transgenic mice.
    Skinner PJ; Vierra-Green CA; Emamian E; Zoghbi HY; Orr HT
    Neuromolecular Med; 2002; 1(1):33-42. PubMed ID: 12025814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Senseless makes sense for spinocerebellar ataxia-1.
    Khurana V; Fulga TA; Feany MB
    Nat Neurosci; 2005 Nov; 8(11):1422-4. PubMed ID: 16251977
    [No Abstract]   [Full Text] [Related]  

  • 8. Neurodegeneration: a question of balance.
    Thompson LM
    Nature; 2008 Apr; 452(7188):707-8. PubMed ID: 18401401
    [No Abstract]   [Full Text] [Related]  

  • 9. Nuclear localization or inclusion body formation of ataxin-2 are not necessary for SCA2 pathogenesis in mouse or human.
    Huynh DP; Figueroa K; Hoang N; Pulst SM
    Nat Genet; 2000 Sep; 26(1):44-50. PubMed ID: 10973246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduction of Purkinje cell pathology in SCA1 transgenic mice by p53 deletion.
    Shahbazian MD; Orr HT; Zoghbi HY
    Neurobiol Dis; 2001 Dec; 8(6):974-81. PubMed ID: 11741393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hosting neurotoxicity in polyglutamine disease.
    Liu N; Bonini NM
    Cell; 2006 Dec; 127(7):1299-300. PubMed ID: 17190592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hsp70/Hsc70 regulates the effect phosphorylation has on stabilizing ataxin-1.
    Jorgensen ND; Andresen JM; Pitt JE; Swenson MA; Zoghbi HY; Orr HT
    J Neurochem; 2007 Sep; 102(6):2040-2048. PubMed ID: 17540008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The ins and outs of a polyglutamine neurodegenerative disease: spinocerebellar ataxia type 1 (SCA1).
    Orr HT
    Neurobiol Dis; 2000 Jun; 7(3):129-34. PubMed ID: 10860780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathologic investigation of a family with expanded SCA8 CTA/CTG repeats.
    Ito H; Kawakami H; Wate R; Matsumoto S; Imai T; Hirano A; Kusaka H
    Neurology; 2006 Oct; 67(8):1479-81. PubMed ID: 17060579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neurodegeneration in the polyglutamine diseases: Act 1, Scene 1.
    Nussbaum R; Auburger G
    Nat Neurosci; 2000 Feb; 3(2):103-4. PubMed ID: 10649562
    [No Abstract]   [Full Text] [Related]  

  • 16. Spinocerebellar ataxias.
    Zoghbi HY
    Neurobiol Dis; 2000 Oct; 7(5):523-7. PubMed ID: 11042068
    [No Abstract]   [Full Text] [Related]  

  • 17. Boat, an AXH domain protein, suppresses the cytotoxicity of mutant ataxin-1.
    Mizutani A; Wang L; Rajan H; Vig PJ; Alaynick WA; Thaler JP; Tsai CC
    EMBO J; 2005 Sep; 24(18):3339-51. PubMed ID: 16121196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dynamic mutation and human disorders: the spinocerebellar ataxias (review).
    Costa Lima MA; Pimentel MM
    Int J Mol Med; 2004 Feb; 13(2):299-302. PubMed ID: 14719138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intranasal administration of IGF-I improves behavior and Purkinje cell pathology in SCA1 mice.
    Vig PJ; Subramony SH; D'Souza DR; Wei J; Lopez ME
    Brain Res Bull; 2006 May; 69(5):573-9. PubMed ID: 16647585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia.
    Xia H; Mao Q; Eliason SL; Harper SQ; Martins IH; Orr HT; Paulson HL; Yang L; Kotin RM; Davidson BL
    Nat Med; 2004 Aug; 10(8):816-20. PubMed ID: 15235598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.